JDD March Issue Highlights and Editor Picks
Below are the issue highlights and Editor Picks for the March issue of JDD!
Papp and Lebwohl review clinical data on the use of biologics in moderate-to-severe psoriasis, identifying which biologics may offer the quickest results in Onset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis.
In Clinical Insights About Onychomycosis and Its Treatment: A Consensus, au …
Below are the issue highlights and Editor Picks for the March issue of JDD!
Papp and Lebwohl review clinical data on the use of biologics in moderate-to-severe psoriasis, identifying which biologics may offer the quickest results in Onset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis.
In Clinical Insights About Onychomycosis and Its Treatment: A Consensus, au … Continue reading "JDD March Issue Highlights and Editor Picks"
Question 1
In your JDD podcast interview, you mentioned that about 50-60% of your patients with LPP respond to naltrexone. Have you seen any similarities between these responders that could help dermatologists identify which patients would be good candidates for naltrexone as an adjunctive therapy?
Answer
"No I have not seen any similarities. The response is unpredictable."
Quest …